The type V intermediate filament lamins are the principal components of the nuclear matrix, including the nuclear lamina. Lamins are divided into A-type and B-type, which are encoded by three genes, LMNA, LMNB1, and LMNB2. The alternative splicing of LMNA produces two major A-type lamins, lamin A and lamin C. Previous studies have suggested that lamins are involved in cancer development and progression. A-type lamins have been proposed as biomarkers for cancer diagnosis, prognosis, and/or follow-up. The aim of the present study was to investigate lamins in cancer cells from metastatic pleural effusions using immunofluorescence, western blotting, and flow cytometry. In a sub-group of lung adenocarcinomas, we found reduced expression of lamin A but not of lamin C. The reduction in lamin A expression was correlated with the loss of epithelial membrane antigen (EMA)/MUC-1, an epithelial marker that is involved in the epithelial to mesenchymal transition (EMT). Finally, the lamin A expression was inversely correlated with the number of metastatic sites and the WHO Performance status, and association of pleural, bone and lung metastatic localizations was more frequent when lamin A expression was reduced. In conclusion, low lamin A but not lamin C expression in pleural metastatic cells could represent a major actor in the development of metastasis, associated with EMT and could account for a pejorative factor correlated with a poor Performance status.
Introduction
Previous studies have suggested that lamins are involved in tumor development and progression [17] . Variations in lamin localization and/or expression levels have been reported in several cancer subtypes [18, 19] . The heterogeneous expression of lamin A/C has been described [3, 14] , primarily using western blots and immunohistochemical staining, in cancer cells obtained from colorectal [6, [20] [21] [22] , gut [23] , gastric [6] , lung [18, 19] , breast [1, 24] , prostate [9, 25, 26] , testis [27] , skin [28, 29] hematologic [10] , cervical [30] , endometrial [31] and ovarian [32, 33] tumors. Opposite results have been reported concerning the prognosis associated with a reduced or lack of expression of lamin A/C in gastric and advanced colon carcinomas [6, [21] [22] [23] . In lung cancer, only a few older studies in cell lines or human tissues have shown reduced lamin A/C expression in small cell lung cancer (SCLC) in contrast with non-SCLC [17] [18] [19] . A few publications have described decreased expression of B-type lamins in gastric and colon carcinomas [23] and in some lung adenocarcinomas [18] , whereas the reverse was observed in prostate carcinoma [25, 26] .
In addition to these quantitative abnormalities, the aberrant cytoplasmic localization of Aand B-type lamins has also been observed in some colon, gastric, and pancreatic cancer and in non-SCLC cells [17, 23] .
Altogether, these studies propose lamin expression as a biomarker for cancer diagnosis, prognosis, and/or follow-up [14] . However, previous studies have only analyzed human cancer cell lines and lung cancer tissues from biopsies.
The aim of the present study was to investigate lamins A, C, and B1 as potential biomarkers in cancer cells from metastatic pleural effusions.
Materials and methods

Study design
This study was an observational study with no intervention. Patients were recruited in the Thoracic Oncology, Pleural Disease, and Interventional Pulmonology Department at Marseille North Hospital. The study was registered on the ClinicalTrials.gov web site (identifier: NCT01284777). The protocol was approved by the Marseille Ethical Committee (Comité de Protection des Personnes Sud Méditerranée I-References number: 2010-A00295-34) and performed in accordance with the Declaration of Helsinki. Subjects provided informed written consent before participation.
Cytological analysis
Pleural effusions were received in the Cell Biology Laboratory at La Timone Hospital of Marseille for conventional cytological diagnosis. Briefly, a fraction of the fresh sample was cytospun (Thermo Electron Corporation, Cheshire, United Kingdom) at 450 g for 3 minutes, and another portion was smeared from the sediment after centrifugation (Jouan, Saint-Herblain, France) at 600 g for 5 minutes.
The slides were air-dried or fixed in acetone and methanol and then stained with MayGrunwald-Giemsa (MGG) or Papanicolaou stains, respectively. The remaining fraction of the sample was used to prepare slides and cell pellets and was stored at -70˚C until use.
Using a light microscope (Leica, Wetzlar, Germany), malignant cells were manually counted, and conventional cytological analysis was completed by immunocytochemical phenotyping. Histological confirmation was achieved in most cases (90%) by conventional analysis and immunohistochemistry on paraffin sections. For the other patients, biopsy and pathological examination could not be performed. Therefore, histologic subtype and primitive tumor localization were defined based on the cytology only associated with the physical examination and radiological imaging according to international recommendations [34] .
Primary antibodies used for immunofluorescence (IF) and/or western blotting (WB)
The following primary antibodies were used for immunofluorescence (IF) For IF, the following isotype antibodies were used as negative controls: mouse IgG (015-000-003, Jackson ImmunoResearch, Suffolk, UK); and rabbit IgG (AB-105-C, R&D, Minnesota, United States).
Dermal fibroblast culture and total protein extraction
The culture and storage of control dermal fibroblasts were performed by the Biological Resource Center of the Department of Medical Genetics (Marseille Timone Hospital).
Cells were cultured in DMEM (Life Technologies) containing 20% FBS (Life Technologies), 2 mM L-glutamine (Life Technologies), and 2X penicillin-streptomycin (Life Technologies) at 37˚C in a humidified atmosphere containing 5% CO 2 . Total fibroblast proteins were extracted (1% Triton X100, 0.1% SDS, 0.5% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 20 mM Tris-HCl pH 7.5, 1X Complete EDTA-free protease inhibitor cocktail, 1 mM Na 3 VO 4 , 1 mM PMSF). Cells were sonicated twice (30 seconds each), incubated at 4˚C for 30 minutes, and then centrifuged at 10,000 g for 10 minutes. Protein concentrations were determined with the BCA™ Protein Assay (Thermo Scientific) according to the manufacturer's instructions [35] . Dermal fibroblasts were used as controls in western blot experiments.
Nuclear protein extraction from pleural effusion cells
Nuclear proteins were extracted from frozen cell pellets [36] . Briefly, cells were incubated during centrifugation (10 min, 800 g, 4˚C) in lysis buffer #1 (10 mM Tris HCl pH 7.5, 30 mM NaCl, 3 mM MgCl 2 , 1 mM PMSF, 0.5 μg/ml aprotinin, 0.5% NP40, and 1X Complete EDTAfree protease inhibitor cocktail (Roche, Meylan, France)).
The supernatant was then removed, and the pellet was washed and incubated for 1 h at 4˚C in lysis buffer #2 (50 mM Tris HCl pH 7.5, 250 mM sucrose, 5 mM MgSO 4 , 1 mM PMSF, 0.5 μg/ml aprotinin, 0.5% NP40, 500 kU/ml DNase (D-5025, Sigma), 25 kU/ml RNase (D-5503, Sigma), and 1X Complete EDTA-free protease inhibitor cocktail). After centrifugation (800 g, 15 minutes, 4˚C), the supernatant was removed, and the pellet was dissolved in 1.6 M NaCl. Protein concentrations were determined using the BCA™ Protein Assay (Thermo Scientific, Courtaboeuf, France) according to the manufacturer's instructions.
Western blotting and lamin quantification
Proteins were extracted and analyzed by a standard western blotting procedure, described as follows.
Protein lysates were separated on Criterion™ XT 7% Tris-Acetate precast gels (345-0135, Bio-Rad, California, United States) and transferred to Immobilon-FL PVDF membranes (Merck-Millipore). Membranes were blocked for one hour in 1:2 blocking buffer for nearinfrared fluorescent western blotting (Rockland, Pennsylvania, United States). The blocked membranes were incubated with primary antibodies for one hour at RT and then washed and incubated with IR-Dye-conjugated secondary antibodies for one hour at RT. Bound antibodies were detected and analyzed on an Odyssey 1 V3.0 imaging system (LI-COR Biosciences, Homburg, Germany) according to the manufacturer's instructions. Secondary antibodies conjugated with IR-Dye 800 or 680 were used according to the manufacturer's instructions (926-32212, 926-32214, 926-32223, 926-32224, 1/5000, LI-COR 1 Biosciences) [37] . The quantities of lamin A, C, and B1 proteins were measured by fluorescence at infrared wavelengths. Lamin A expression was normalized to the total amount of lamins A and C, and a ratio was established [Lamin A / (Lamin A + Lamin C)].
Immunofluorescence microscopy
Cells were centrifuged (450 g, 5 minutes) in a Cytospin (Thermo Electron Corporation), and slides were stored at -70˚C prior to use. Cells were immunostained using a previously described protocol (37) . Briefly, after 15 minutes of fixation at room temperature (RT) in a 4% paraformaldehyde + 2% sucrose solution, cells were permeabilized using a permeabilization buffer (0.5% Triton X-100, 50 mM NaCl, 300 mM sucrose, 20 mM HEPES pH 7.5, 3 mM MgCl 2 ) for 3 minutes at RT. The cells were then incubated with the primary antibodies for 40 minutes at 37˚C. After washing, the cells were incubated with secondary antibodies (A11001, A11055, A11012; Life Technologies, Saint-Aubin, France; 1/400) for 20 minutes at 37˚C. The nuclei were counterstained with DAPI (0.1 μg/mL, Sigma, Lyon, France) for 10 minutes at RT. The slides were mounted using FluorSave™ reagent (Merck Millipore) and were observed on a fluorescence microscope (ApoTome.2 Zeiss).
Flow cytometry
A flow cytometry analysis was performed on adenocarcinoma cells from seven patients, on the remaining available samples.
Cells were stored in medium containing 90% FBS and 10% DMSO at -70˚C until use. Red blood cells were lysed before storage using NH 4 Cl lysis buffer. Cells were fixed at RT in 4% paraformaldehyde solution and washed in PBS containing 0.2 M glycine prior to permeabilization at RT using the homemade permeabilization buffer detailed in the immunofluorescence method. Cells were then incubated in PBS containing 2% BSA for 20 minutes and for one hour with the following antibodies: anti-CD45-PECy7 ( 
Statistical analyses
The statistical analysis was performed with the Prism software (GraphPad Software Inc., California, United States). Significant differences were determined using t-test or Mann-Whitney test; Chi-square or Fisher tests were conducted to evaluate the differences between groups for qualitative variables; and correlations were established using Pearson or Spearman tests, depending on the Gaussian distribution of the values.
All statistical results were 2-sided and a P-value < 0.05 was considered significant.
Results
Participant characteristics
Patients diagnosed with a metastatic pleural effusion from lung adenocarcinoma in our institution were prospectively recruited. 32 patients were enrolled because their pleural effusion contained at least 20% adenocarcinoma cells. Patient demographics and clinical and cytological data were prospectively collected, at the time of the pleural puncture ( Table 1 ). The cohort included 14 females and 18 males, with a median age of 69 years (range 50-96 years).
Reduced expression of lamin A but not of lamin C was observed in a sub-group of lung adenocarcinomas Lamin A, B1, and C bands were observed by western blot at the expected sizes (72 kDa, 68 kDa, and 65 kDa, respectively).
A strong reduction in lamin A but not in lamin C expression was specifically observed in 12 (37.5%) patients with lung adenocarcinoma pleural metastasis using a mouse anti-lamin A/C antibody (Jol2) (Panel A in Fig 1 and S1 Fig) . The lamin ratio [r = A / (A + C)] distinguished two groups of lung adenocarcinoma patients; 37.5% (12/32) of patients are in the low lamin A expression group with a ratio Fig 1) . In accordance with Western blot analysis, immunofluorescence experiments showed, in cancer cells, a variable expression of lamin A depending on patient group (low or high lamin A expression group), whereas positive nuclear staining with anti-lamin C antibody was consistently observed. As shown in Fig 2, most adenocarcinoma cells from patients from high lamin A expression group were intensively positive for lamin A antibody staining (ex: Pt51), whereas a high part of adenocarcinoma cells from patients from low lamin A expression group showed a weak staining (ex: Pt58).
In normal leukocytes, lamin A/C expression was very weak or absent. Cytological analysis showed that cancer cells exhibited nuclear morphological abnormalities, such as dyskaryosis, blebs, and micronuclei. No aberrant cytoplasmic localization of lamin A/C was observed (Fig 2) .
Reduced lamin A expression was correlated with the loss of EMA/MUC-1 in adenocarcinoma cells analysis by positive staining with the LIVE/DEAD 1 viability marker and CD45, respectively.
CD45-negative cells were considered adenocarcinoma cells (Panels A and B in Fig 3) , as normal mesothelial cells accounted for less than 2% of these pleural effusions. Lamin A and EMA (epithelial membrane antigen, also known as MUC-1) protein expression was then specifically studied in these adenocarcinoma cells (Panels C and D in Fig 3) . Three main adenocarcinoma cell populations were defined: cells expressing both lamin A and EMA (LamA+/EMA+); cells lacking both lamin A and EMA (LamA-/EMA-); and cells expressing lamin A associated with the loss of EMA (LamA+/EMA-). The percentages of these three main cell populations differed between patients (Panel D in Fig 3 and Table 2 ). A fourth minor cell population expressing EMA but lacking lamin A (LamA-/EMA+) was considered negligible because it represented less than 4% of cells. All patients exhibited an adenocarcinoma cell population completely lacking lamin A, but the percentage of this cell population differed between patients, depending on patient group (low or high lamin A expression group) (Panels C and D in Fig 3 and Table 2 ). For example, as shown in Table 2 , 18.7% of adenocarcinoma cells from Patient 16 (Pt16, from high lamin A expression group) were negative for lamin A staining whereas 54.8% of adenocarcinoma cells from Patient 45 (Pt45, from low lamin A expression group) lacked lamin A expression. Thus, these results illustrate that in patients from low lamin A expression group (ex: Pt45), adenocarcinoma cell population completely lacking lamin A is predominant compared to patients from high lamin A expression group (ex: Pt16) (18.7% and 54.8%, respectively).
Moreover, the expression marker for carcinoma cell differentiation, EMA, was also lacking in some adenocarcinoma cells (Panel D in Fig 3) , and interestingly, the percentage of lamin A+ adenocarcinoma cells was positively correlated with the percentage of EMA+ cells (p = 0.0123) (Panel E in Fig 3) . These flow cytometry experiments identified a sub-population of metastatic lung adenocarcinoma cells lacking lamin A expression, and we showed that this decrease in lamin A expression was correlated with the loss of EMA/MUC-1.
Lamin A expression in lung adenocarcinoma cells was inversely correlated with the number of metastatic sites and the WHO Performance status
Clinical data from the 32 patients with lung adenocarcinoma were collected at the time of the pleural puncture and analyzed according to their high or low lamin A expression status (Table 1) .
Interestingly, the number of total metastatic sites was inversely correlated with the lamin ratio [A / (A + C)], reflecting lamin A expression (p = 0.04; Pearson test) (Panel A in Fig 4) . The association of bone, lung and pleural metastasis was more frequently observed in patients of the low lamin A expression group (9/12; 75%) compared with the patients belonging to the high lamin A expression group (5/20; 25%) (p = 0.01; Fisher test).
Moreover, patients from the low lamin A group exhibited a higher Performance status score than those from the high lamin A group (2 vs 1, respectively; p = 0.007, unpaired t-test) and the patients repartition was statistically different according the lamin A expression group (p = 0.037; Chi-square test) (Panel B in Fig 4) . In addition, the Performance status score was inversely correlated with the lamin ratio [A / (A + C)] (p = 0.01; Spearman test) (Panel C in Fig 4) .
Discussion
We combined immunofluorescence, western blotting, and flow cytometry for the first time to study lamins in cancer cells from metastatic pleural effusions. Previous studies have already described lamin expression abnormalities in cancer cells but have been restricted to cancerous lung tissues from primitive tumor biopsies and have relied primarily on immunohistochemical methods [17] [18] [19] . Interestingly, we reported reduced expression of lamin A but not of lamin C in a sub-group of metastatic lung adenocarcinoma patients. No variations in lamin B1 expression were observed in these cells.
Lamins A and C, which are encoded by the same LMNA gene, both result from alternative splicing in exon 10, which produces two different mRNAs that encode prelamin A (the precursor of lamin A) and lamin C [4] . Therefore, we hypothesize that the loss of lamin A but not lamin C expression in pleural metastatic adenocarcinoma cells could result from regulation by miRNAs or splicing factors.
Recent publications reported that miR-9 negatively controls lamin A but not lamin C expression due to the specific targeting of lamin A mRNA in neural cells [38, 39] . It would be thus very interesting to investigate miR-9 expression using RT-qPCR assays in metastatic pleural effusions from lung adenocarcinoma in the two lamin A expression groups. As these samples contained cancer cells mixed with miR-9 expressing leukocytes, it would be useful to correlate the level of miR-9 with lamin expression specifically in metastatic cells after their isolation by FACS selection or using magnetic beads.
The splicing factors involved in the alternative production of lamins A and C are still unknown. The serine-arginine (SR)-rich splicing factor 1 (SRSF1) controls LMNA pre-mRNA alternative splicing [40] , leading to the production of progerin (the truncated prelamin A protein produced in HGPS (Hutchinson-Gilford Progeria Syndrome) cells and during physiological aging) [4, 41] . SRSF1 has been proposed as a proto-oncogene because it is overexpressed in many cancers [42] . In particular, in lung adenocarcinoma, SRSF1 overexpression is associated with a more aggressive phenotype, the presence of metastases, and chemotherapy resistance [43] . Progerin was found to be expressed in many human cancer cell lines, and its ectopic expression in a prostate cancer cell line led to enhanced growth and stronger tumorigenic potential in vivo after subcutaneous injection into nude mice [44] .
Our flow cytometry analyses identified a sub-population of metastatic lung adenocarcinoma cells lacking lamin A expression, and we showed that this decrease in lamin A expression was correlated with the loss of EMA/MUC-1.
The epithelial to mesenchymal transition (EMT) is characterized by the downregulation of epithelial differentiation markers, such as EMA, and is associated with the upregulation of mesenchymal markers [45, 46] . EMT increases cell motility and invasiveness and is correlated with invasive tumor metastasis and poor prognosis [43, [46] [47] [48] . Nevertheless, several publications have described EMA as an EMT inducer due to glycosylation and overexpression in carcinomas [47, 48] . In future studies, it would be useful to compare both lung adenocarcinoma metastatic cells and primary tumors to analyze EMA and lamin A expression, together with other EMT markers that are already known to evolve during tumor progression or metastasis.
Some studies have reported SRSF1 and miR-9 involvement in EMT during lung cancer [43, 49] . Metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1), a long, non-coding nuclear RNA, is known as a poor prognostic marker and a predictive marker for metastasis development in lung cancer; it targets genes involved in cell migration, tumor growth and the EMT [50] [51] [52] [53] . Interestingly, miR-9 negatively regulates the expression of MALAT-1 [54] , and MALAT-1 is implicated in the regulation of SRSF1 [50, 55, 56] .
Therefore, it would be of interest to explore and concomitantly correlate miR-9, SRSF1 and MALAT-1 expression in lung adenocarcinoma metastatic cells and in primary tumors, and also to correlate their levels with EMT markers and lamin A expression. Furthermore, as MALAT-1 is detectable in peripheral human blood and has been proposed as a blood biomarker of NSCLC [57] , we could investigate this new parameter in a prospective cohort.
Moreover, our work showed that the lamin ratio, reflecting lamin A expression, was inversely correlated with the number of total metastatic sites, with a frequent association of lung, pleural and bone metastasis in patients with low lamin A expression. Our data are consistent with a recent publication that described a reduction of lamin A but not of lamin C expression in primitive epithelial ovarian cancer tissues associated with metastasis potential and poor prognosis [32] . Similarly, in prostate carcinoma cells, reduced amounts of lamin A were Low lamin A expression as pejorative factor in metastatic lung cancer correlated to an increased risk for lymph node metastasis [26] . Furthermore, the number of metastatic sites has already been linked to overall survival in lung adenocarcinoma [58, 59] . Interestingly Lee et al., also demonstrated that bone is one of the most frequent metastasis localization in lung adenocarcinoma [58, 59] whereas the presence of bone metastases is considered as an adverse prognostic factor associated with shorter survival [60] .
Furthermore, miR-9 seems to be involved in tumorigenesis and cancer progression. It can act as an oncogene or a tumor suppressor; several publications described various miR-9 expression patterns between cancerous and adjacent normal tissues or depending on the tumor type [49, [61] [62] [63] . Few publications have suggested that miR-9 promotes the metastasis of non-small cell lung cancer (NSCLC), and its up-regulation has been associated with poor prognosis [62, 63] .
However, epigenetic miR-9 silencing was described as a poor prognosis in NSCLC primary tumors, especially in squamous cell carcinoma, and as a predictive marker of lymph node metastasis by cancer cell lines derived from other tumor types [61, 62] .
Finally, our work showed that the reduction of lamin A expression was correlated with a poor WHO Performance status, which is considered as a gold standard prognostic measure [64] . It is proposed as the most established factor for assessing prognosis and is advised in guidelines for lung cancer treatment [64, 65] . Indeed, the Performance status represents a major criteria for treatment decision in advanced lung cancer as patients with a poor Performance status are expected to be unfit for conventional treatments [64] [65] [66] .
Furthermore, the Performance status has been closely linked to overall survival in advanced lung adenocarcinoma, as a poor Performance status was associated with a reduced survival [58, 59, 64] .
These publications emphasize here the probable link of a low lamin A expression with a poor prognosis and a shorter survival outcome, which need to be confirmed in a further study.
Conclusions
In conclusion, our work, which is a pilot study, already showed significant results, suggesting that low lamin A but not lamin C expression in pleural metastatic cells could represent a major actor in the development of metastasis, associated with EMT and could account for a pejorative factor correlated with a poor Performance status.
These results should lead to better understand at the mechanistic level, the metastasis development in which nuclear matrix, and lamins in particular, could have a central role. Moreover, we intend to confirmed our results and to analyze EMT markers in a new prospective large study to emphasize the loss of lamin A as a poor prognostic marker and to understand the link between a lack of lamin A in lung adenocarcinoma cells and their metastatic potential. 
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